average-risk adults

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking blood test for colorectal cancer screening in average-risk adults over the age of 45. Developed by Guardant Health, this test is the first of its kind to receive FDA approval as a primary screening tool for colorectal cancer.

Guardant Health announces this significant development, emphasizing the test's potential to revolutionize colorectal cancer screening. By offering a less invasive alternative to traditional methods such as colonoscopies, the blood test could encourage more people to undergo regular screenings. . .